Patients with metastatic non-small cell lung cancer and targetable molecular alterations in Germany. Treatment and first outcome data from the prospective German Registry Platform CRISP (AIO-TRK-0315)

Mapping Intimacies ◽

10.1055/s-0039-3403363 ◽

2020 ◽

Author(s):

F Griesinger ◽

WEE Eberhardt ◽

A Nusch ◽

M Reiser ◽

MO Zahn ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Outcome Data ◽

Small Cell ◽

Small Cell Lung ◽

Molecular Alterations ◽

German Registry

Download Full-text

Patients with metastatic non-small cell lung cancer and targetable molecular alterations in Germany. Treatment and first outcome data from the prospective German Registry Platform CRISP (AIO-TRK-0315)

Annals of Oncology ◽

10.1093/annonc/mdz260.074 ◽

2019 ◽

Vol 30 ◽

pp. v639-v640

Author(s):

F. Griesinger ◽

W.E.E. Eberhardt ◽

A. Nusch ◽

M. Reiser ◽

M.-O. Zahn ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Outcome Data ◽

Small Cell ◽

Small Cell Lung ◽

Molecular Alterations ◽

German Registry

Download Full-text

Patients with metastatic non-small cell lung cancer without molecular alterations or PD-L1 expression in Germany: Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)

Annals of Oncology ◽

10.1093/annonc/mdz260.022 ◽

2019 ◽

Vol 30 ◽

pp. v616

Author(s):

F. Griesinger ◽

W.E.E. Eberhardt ◽

H.-R. Bruch ◽

J. Rauh ◽

E. von der Heyde ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Molecular Alterations ◽

German Registry

Download Full-text

Patients with metastatic non-small cell lung cancer without molecular alterations or PD-L1 expression in Germany. Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)

10.1055/s-0039-3403090 ◽

2020 ◽

Author(s):

F Griesinger ◽

WEE Eberhardt ◽

HR Bruch ◽

J Rauh ◽

E von der Heyde ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Molecular Alterations ◽

German Registry

Download Full-text

A Study of Alectinib, Entrectinib, or Vemurafenib Plus Cobimetinib in Participants With Stages I-III Non-Small Cell Lung Cancer With ALK, ROS1, NTRK, or BRAF v600E Molecular Alterations

Case Medical Research ◽

10.31525/ct1-nct04302025 ◽

2020 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Braf V600e ◽

Small Cell Lung ◽

Molecular Alterations

Download Full-text

Association of programmed cell death 1 ligand (PD-L1) expression with molecular alterations in non-small cell lung cancer (NSCLC) patients (pts): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort

Annals of Oncology ◽

10.1093/annonc/mdx390.002 ◽

2017 ◽

Vol 28 ◽

pp. v573-v574

Author(s):

K.M. Kerr ◽

E. Thunnissen ◽

U. Dafni ◽

A. Soltermann ◽

S. Finn ◽

...

Keyword(s):

Lung Cancer ◽

Cell Death ◽

Programmed Cell Death ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Molecular Alterations ◽

Programmed Cell Death 1 ◽

Nsclc Patients

Download Full-text

Abstract B179: Final results of a phase 1 study of cabozantinib (Cabo) in Japanese patients (pts) with expansion cohorts in non-small cell lung cancer (NSCLC) with defined molecular alterations

10.1158/1535-7163.targ-15-b179 ◽

2015 ◽

Author(s):

Hiroshi Nokihara ◽

Makoto Nishio ◽

Noboru Yamamoto ◽

Yutaka Fujiwawa ◽

Hidehito Horinouchi ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase 1 ◽

Japanese Patients ◽

Small Cell ◽

Small Cell Lung ◽

Phase 1 Study ◽

Molecular Alterations

Download Full-text

Clinical Comparison of First-Line Platin Chemotherapy Regimens In Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) Using German Registry Data

Value in Health ◽

10.1016/j.jval.2017.08.112 ◽

2017 ◽

Vol 20 (9) ◽

pp. A416-A417

Author(s):

JS Haas ◽

D Meise ◽

A Ogbonnaya ◽

S Braun ◽

M Eaddy ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Registry Data ◽

Small Cell Lung ◽

First Line ◽

Clinical Comparison ◽

German Registry

Download Full-text

Stereotactic ablative radiotherapy (SABR) for early stage, non-small cell lung cancer (NSCLC): two year clinical outcome data from the Oxford Cancer Centre (OCC)

Lung Cancer ◽

10.1016/s0169-5002(20)30106-9 ◽

2020 ◽

Vol 139 ◽

pp. S33

Author(s):

L. Pascal ◽

S. O’Cathail ◽

G. Higgins ◽

D. Ajzensztejn ◽

R. Stuart ◽

...

Keyword(s):

Lung Cancer ◽

Clinical Outcome ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Early Stage ◽

Outcome Data ◽

Small Cell ◽

Stereotactic Ablative Radiotherapy ◽

Small Cell Lung ◽

Cancer Centre

Download Full-text

79P Small cell lung cancer in the young: Characteristics, timeliness and outcome data

Journal of Thoracic Oncology ◽

10.1016/s1556-0864(18)30354-x ◽

2018 ◽

Vol 13 (4) ◽

pp. S43-S44

Author(s):

S. Jiang ◽

Y. Han ◽

Y. Huang ◽

X. Hao ◽

J. Li ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Outcome Data ◽

Small Cell ◽

Small Cell Lung

Download Full-text

Phase I/II study of PF-06463922, an ALK/ROS1 tyrosine kinase inhibitor, in patients with advanced non-small-cell lung cancer harboring specific molecular alterations.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps2620 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS2620-TPS2620 ◽

Cited By ~ 4

Author(s):

Todd Michael Bauer ◽

Alice Tsang Shaw ◽

Ben Solomon ◽

Benjamin Besse ◽

Leonard P. James ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Phase I ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Molecular Alterations

Download Full-text